Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome

Sponsor
Taipei Medical University Shuang Ho Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05539950
Collaborator
(none)
40
1
2
27
1.5

Study Details

Study Description

Brief Summary

In 2022, though the optimized acute medical treatment of COVID-19 was determined, patients often experience the sequelae (also known as post-acute COVID-19 syndrome, the patients might develop cough, breathlessness, fatigue, weakness, impaired activities of daily livings etc.). Until now, there is no consensus for post-acute COVID-19 syndrome management. Previously, the cardiopulmonary rehabilitation revealed significant benefits in heart failure or chronic obstructive pulmonary disease. The aims of the study are demonstrating the benefits and safety of cardiopulmonary rehabilitations in patients previously admitted to hospital because of COVID-19 with sequelae.

Condition or Disease Intervention/Treatment Phase
  • Other: Cardiopulmonary rehabilitation
  • Other: Health education
N/A

Detailed Description

PURPOSE: To demonstrate the benefits and safety of cardiopulmonary rehabilitations in patients previously admitted to hospital because of COVID-19 with sequelae.

METHODS: The participants will be divided into two groups: one with cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total with lifestyle modification (experimental group); and the other with lifestyle modification and health education (active-controlled group). Before and after the interventions, several endpoints in interested are performed by the physicians or the research assistants, including cardiopulmonary exercise training (CPET), 6-minute-walk-test (6MWT), pulmonary function tests (PFT), and quality of life (QoL, we plan to use SF-36) questionnaire.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cardiopulmonary rehabilitation with health education

The participants will participate in cardiopulmonary rehabilitations programs under the supervision of therapists 3 times a week, 12 weeks in total. Recommendations for individualized exercise prescription and lifestyle modification will be given to the participants as well.

Other: Cardiopulmonary rehabilitation
Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).

Other: Health education
Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.

Active Comparator: Health education

The participants will be given recommendations for individualized exercise prescription and lifestyle modification.

Other: Health education
Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.

Outcome Measures

Primary Outcome Measures

  1. Changes in Cardiopulmonary exercise testing (CPET) [Baseline, Week 12]

    CPET is a non-invasive examination, which provides assessment of the integrative exercise responses involving the pulmonary, cardiovascular, hematopoietic, neuropsychological, and skeletal muscle systems. It permits the evaluation of both submaximal and peak exercise responses. CPET is currently act as a clinical applications for the evaluation of undiagnosed exercise intolerance and for the objective determination of functional capacity and impairment.

Secondary Outcome Measures

  1. Changes in 6 minutes walking test (6MWT) [Baseline, Week 12]

    6MWT is a commonly used test for the objective assessment of functional exercise capacity for the management of patients with moderate-to-severe pulmonary disease. This test does not require complex equipment or technical expertise. The participant is asked to walk as far as possible along a 30-m minimally trafficked corridor for a period of 6 min with the primary outcome measure being the 6-min walk distance (6MWD) measured in meters.

  2. Changes in Pulmonary function test (PFT) [Baseline, Week 12]

    PFT is used in investigating and monitoring of patients with respiratory pathology. PFT allows physicians to quantify the severity of the pulmonary disease, follow it up over time, and assess its response to treatment.

  3. Changes in 36-Item Short Form Survey (SF-36) [Baseline, Week 12]

    SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. This questionnaire includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • be willing and able to provide written informed consent and comply with all procedures required by the protocol

  • be 20 - 80 years of age at the time of signing the Informed Consent Form

  • diagnosed with COVID-19 with PCR and admitted with at least moderate COVID-19 disease (with clinical symptoms or imaging evidence of low respiratory tract involvement)

  • diagnosed with COVID-19 for over 4 weeks but less than 2 years with fatigue, shortness of breath, cough, weakness, or impairments of activities of daily life

  • able to cooperate with the rehabilitation programs and cycling

Exclusion Criteria:
  • Patients under 20-year-old or over 80-year-old, pregnant, prisoners

  • Patients without national health insurance in Taiwan

  • The patient cannot follow instructions or cycling

Contacts and Locations

Locations

Site City State Country Postal Code
1 Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare Taipei Taiwan 235

Sponsors and Collaborators

  • Taipei Medical University Shuang Ho Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hung-Chou Chen, Director and Attending Physician, Taipei Medical University Shuang Ho Hospital
ClinicalTrials.gov Identifier:
NCT05539950
Other Study ID Numbers:
  • TMU-IJRB-N202208050
First Posted:
Sep 14, 2022
Last Update Posted:
Sep 14, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hung-Chou Chen, Director and Attending Physician, Taipei Medical University Shuang Ho Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2022